Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 189 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Co-Infection Clear all
Completed No phase listed Observational

Eliminating Hepatitis C Virus

NCT03401697
View directory record Official record
Conditions
Hepatitis C, HIV, Type2 Diabetes
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

NCT02071082
View directory record Official record
Conditions
HIV, HBV
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Jul 22, 2026, 10:59 AM EDT
Completed No phase listed Observational

Study on Immunopathogenesis in HIV and Hepatitis C Coinfection

NCT01296529
View directory record Official record
Conditions
HIV Infection, Hepatitis C Infection, Fibrosis, Inflammation
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Jul 22, 2026, 10:59 AM EDT
Completed No phase listed Observational

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

NCT00004850
View directory record Official record
Conditions
Hepatitis C, Hepatitis B
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 10:59 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

NCT02016924
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions
ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
4 Weeks to 17 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
7
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 22, 2026, 10:59 AM EDT
Recruiting No phase listed Observational

Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

NCT01904188
View directory record Official record
Conditions
Sepsis, Systemic Inflammatory Response Syndrome, Infection Mixed, Infection, Bacterial, Infection, Fungal, Infection, Coronavirus, Antibiotic Resistance Genes, Human Genome Analysis
Interventions
Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z - now using In-Dx along with other developed techniquesregularly)
Device
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2032
U.S. locations
2
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acceptance and Commitment Therapy for Aging People Living With HIV in Chronic Pain

NCT03699020
View directory record Official record
Conditions
HIV/AIDS, Chronic Pain
Interventions
Acceptance and Commitment Therapy (ACT), Chronic Pain Education
Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 22, 2026, 10:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The DC Cohort Longitudinal HIV Status Neutral Study

NCT01206920
View directory record Official record
Conditions
HIV, AIDS
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
Not listed
Enrollment
19,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2041
U.S. locations
14
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 22, 2026, 10:59 AM EDT
Recruiting Phase 1 Interventional

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

NCT06559189
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
CD19x22 CAR T
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Months to 30 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

NCT00031343
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
highly active antiretroviral therapy (HAART)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

NCT01479868
View directory record Official record
Conditions
Hepatitis C Virus Genotype-1
Interventions
TMC435, Pegylated interferon alpha-2a, Ribavirin
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

NCT03207750
View directory record Official record
Conditions
Rotavirus Infection, Rotavirus Vaccines
Interventions
Rotarix, Pediarix, Hiberix, Prevenar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Jul 22, 2026, 10:59 AM EDT
Terminated No phase listed Observational

Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)

NCT00340548
View directory record Official record
Conditions
Hemophilia, AIDS
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

NCT03439657
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine GSK1437173A, Prevenar13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
913 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

NCT05064800
View directory record Official record
Conditions
Healthy Participants
Interventions
Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

NCT00711009
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection
Interventions
lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

NCT02625909
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jul 22, 2026, 10:59 AM EDT
Completed No phase listed Observational

HCV/HIV Coinfection: Antiviral Therapy and Fibrosis

NCT01423643
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

NCT00148941
View directory record Official record
Conditions
Tetanus, Acellular Pertussis, Diphtheria
Interventions
SB213503 lot 1, SB213503 lot 2, SB213503 lot 3, Infanrix, IPOL, M-M-R II
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
4,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
24
States / cities
Little Rock, Arkansas • Antioch, California • Daly City, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

NCT02052596
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, Boostrix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
935 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • San Diego, California • Stockbridge, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant Patients

NCT00644761
View directory record Official record
Conditions
Hepatitis B
Interventions
Adefovir Dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

NCT04927585
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 22, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection

NCT02707991
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic
Interventions
Nurse Case Management
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Jul 22, 2026, 10:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiology of H. Pylori Transmission

NCT02740140
View directory record Official record
Conditions
Communicable Diseases
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
1,750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Jul 22, 2026, 10:59 AM EDT